Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure.

Abstract

Acute-on-chronic liver failure (ACLF) is an extreme condition after severe acute exacerbation of chronic hepatitis B; however, the underlying genetic factors involved in its onset and progression are currently unclear. We carried out a genome-wide association study among 399 HBV-related ACLFs (cases) and 401 asymptomatic HBV carriers (AsCs, as controls) without antiviral treatment. The initial findings were replicated in four independent case-control sets (a total of 901 ACLFs and 1686 AsCs). The roles of risk variants on clinical traits of ACLF were also analysed. Among 1300 ACLFs and 2087 AsCs, we identified rs3129859 at human leucocyte antigen (HLA) class II region (chromosome 6p21.32) associated with HBV-related ACLF (combined P <i>_dominant</i> =2.64×10^-20, OR=1.83). Analysis identified <i>HLA-DRB1*12:02</i> as the top susceptible HLA allele associated with ACLF (p=3.94×10^-6, OR=2.05). The association of rs3129859 was robust in ACLF subgroups (ACLFs with liver cirrhosis, p=1.36×10^-16; ACLFs without liver cirrhosis, p=1.52×10^-7), and patients at low-replicative phase (p=6.36×10^-11, OR=2.29) or HBV e antigen-negative chronic hepatitis B phase (p=1.51×10^-14, OR=1.86). Clinical traits analysis in patients with ACLF showed that the risky rs3129859*C allele was also associated with prolonged prothrombin time, faster progression to ascites development and higher 28-day mortality. Our genome-wide association study identified <i>HLA-DR</i> as the major locus for susceptibility to HBV-related ACLF. Our findings highlight the importance of HLA class II restricted CD4+ T-cell pathway on the immunopathogenesis of HBV-related ACLF.